Van Andel Institute researchers have uncovered an alternative metabolic route in cancer cells, whereby β-hydroxybutyrate is converted into cytosolic acetyl-CoA, vital for lipid synthesis and cell proliferation, independent of glucose availability. This non-canonical pathway enhances cancer cells’ metabolic flexibility, enabling sustained growth under variable nutrient conditions and challenging traditional views of tumor metabolism. Understanding such adaptations may inform novel therapeutic strategies targeting cancer metabolism.